Skip to content

Jejunal Neuroendocrine Tumor Well Differentiated Low Or Intermediate Grade C4525626

Published: July 22, 2026Updated: August 20, 2026

A neuroendocrine tumor in the jejunum with favorable cell characteristics and slower growth. Generally has a good outlook with appropriate treatment including surgery and targeted therapies.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Occult gastrointestinal bleeding

Abdominal pain

(gastrointestinal)

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Weight loss

(gastrointestinal)

Nausea

(gastrointestinal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Curative-Intent Surgical Resection

Complete surgical excision of the well-differentiated low-to-intermediate grade neuroendocrine tumor with appropriate lymphadenectomy for accurate staging and optimal outcomes.

surgical
2

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Long-Acting Somatostatin Analogs

Monthly intramuscular injections of long-acting somatostatin analogs to suppress hormone secretion and slow tumor growth in unresectable or metastatic disease.

medication

Additional treatment options

Multidisciplinary Surveillance Protocol

Coordinated follow-up with serial imaging, biochemical markers, and specialist evaluations to detect recurrence or progression early in well-differentiated tumors.

monitoring

Peptide Receptor Radionuclide Therapy

Targeted radiation therapy delivering radioactive isotopes directly to tumor cells expressing somatostatin receptors, used for progressive well-differentiated tumors.

procedure

Stress Management and Physical Activity

Regular moderate exercise and stress reduction techniques to improve quality of life and support immune function during and after neuroendocrine tumor treatment.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Jejunal Neuroendocrine Tumor Well Differentiated Low Or Intermediate Grade C4525626?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Benson AB, Catalano PJ, Chan E, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2023. J Natl Compr Canc Netw. 2023.

guideline2023View source →
2

Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860.

review2020View source →
3

Modlin IM, Oberg K, Chung DC, et al. Gastrointestinal neuroendocrine tumours: a systematic review and meta-analysis of prognostic factors. Neuroendocrinology. 2018;107(3):239-249.

meta_analysis2018
4

Strosberg JR, Weber JM, Feldman M, et al. Profiling of somatostatin receptor subtype expression in jejunal neuroendocrine tumors: implications for peptide receptor radionuclide therapy. Cancer. 2021;127(14):2567-2575.

clinical_trial2021

Medication Comparisons

Compare medications used to treat Jejunal Neuroendocrine Tumor Well Differentiated Low Or Intermediate Grade C4525626. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy